What is claimed is:
1. A method of treating a neoplastic disorder in a mammal in need thereof comprising administering a therapeutically effective amount of a CD23 antagonist to said mammal.
2. The method of claim 1 wherein said CD23 antagonist is selected from the group consisting of CD23 reactive polypeptides, CD23 reactive peptides, CD23 reactive small molecules, and combinations thereof.
3. The method of claim 2 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
4. The method of claim 3 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
5. The method of claim 4 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
6. The method of claim 5 wherein said monoclonal antibody is a chimeric antibody and said chimeric antibody is primatized.
7. The method of claim 6 wherein said primatized antibody is IDEC-152.
8. The method of claim 7 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin’s disease, resistant Hodgkin’s disease high grade, low grade and intermediate grade non-Hodgkin’s lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt’s lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt’s and non-Burkitt’s; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
9. The method of claim 8 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
10. The method of claim 1 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin’s disease, resistant Hodgkin’s disease high grade, low grade and intermediate grade non-Hodgkin’s lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt’s lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved: Burkitt’s and non-Burkitt’s: follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
11. The method of claim 10 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
12. The method of claim wherein said CD23 antagonist is associated with a cytotoxic agent.
13. The method of claim 12 wherein said cytotoxic agent is a radioisotope.
14. The method of claim 1 further comprising the step of administering a chemotherapeutic agent.
15. The method of claim 14 wherein said chemotherapeutic agent comprises an antibody.
16. The method of claim 15 wherein said antibody reacts with or binds to CD19, CD20, CD22, CD40, CD40L. CD52 or B7.
17. The method of claim 14 wherein said chemotherapeutic agent comprises fludarabine.
18. A method of treating a neoplastic disorder in a mammal comprising the steps of:
administering a therapeutically effective amount of at least one chemotherapeutic agent to said mammal; and
administering a therapeutically effective amount of at least one CD23 antagonist to said patient wherein said chemotherapeutic agent and said CD23 antagonist may be administered in any order or concurrently.
19. The method of claim 18 wherein said CD23 antagonist is selected from the group consisting of CD23 reactive polypeptides. CD23 reactive peptides, CD23 reactive small molecules, and combinations thereof.
20. The method of claim 19 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
21. The method of claim 20 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
22. The method of claim 21 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
23. The method of claim 22 wherein said monoclonal antibody is IDEC-152.
24. The method of claim 18 wherein said chemotherapeutic agent comprises an antibody.
25. The method of claim 24 wherein said antibody reacts with or binds to CD19, CD20, CD22, CD40, CD40L, CD52 or B7.
26. The method of claim 18 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin’s disease, resistant Hodgkins disease high grade, low grade and intermediate grade non-Hodgkin’s lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt’s lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt’s and non-Burkitt’s; follicular, predominantly large cell, follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
27. The method of claim 18 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
28. A method of treating B cell chronic lymphocytic leukemia (B-CLL) in a mammal in need thereof comprising administering a therapeutically effective amount of a CD23 antagonist to said mammal.
29. The method of claim 28 wherein said CD23 antagonist is selected from the group consisting of CD23 reactive polypeptides, CD23 reactive peptides, CD23 reactive small molecules and combinations thereof.
30. The method of claim 29 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
31. The method of claim 36 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
32. The method of claim 31 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
33. The method of claim 32 wherein said monoclonal antibody is IDEC-152.
34. The method of claim 28 further comprising the step of administering a chemotherapeutic agent.
35. The method of claim 32 wherein said chemotherapeutic agent comprises an antibody.
36. The method of claim 35 wherein said antibody reacts with or binds to CD19, CD20, CD22, CD40, CD40L, CD52 or B7.
37. The method of claim 34 wherein said chemotherapeutic agent comprises fludarabine.
38. A method of treating a neoplastic disorder in a mammal comprising the steps of
administering a therapeutically effective amount of Rituxan to said mammal; and
administering a therapeutically effective amount of IDEC-152 to said mammal wherein said Rituxan and said IDEC-152 may be administered in any order or concurrently.
39. The method of claim 38 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin’s disease, resistant Hodgkin’s disease high grade, low grade and intermediate grade non-Hodgkin’s lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt’s lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt’s and non-Burkitt’s; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
40. The method of claim 38 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
41. A method of inducing apoptosis in malignant cells comprising contacting said malignant cells with an apoptosis inducing amount of a CD23 antagonist.
42. The method of claim 41 wherein said CD23 antagonist is selected from the group consisting of CD23 reactive polypeptides, CD23 reactive peptides, CD23 reactive small molecules, and combinations thereof.
43. The method of claim 41 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
44. The method of claim 43 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
45. The method of claim 44 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
46. The method of claim 44 wherein said monoclonal antibody is IDEC-152.
47. The method of claim 41 further comprising the step of contacting said malignant cells with a chemotherapeutic agent.
48. The method of claim 47 wherein said chemotherapeutic agent comprises an antibody.
49. The method of claim 48 wherein said antibody reacts with or binds to CD19, CD20, CD22, CD40, CD40L, CD52 or B7.
50. The method of claim 41 wherein said malignant cells are contacted in vivo.
51. A kit useful for the treatment of a mammal suffering from or predisposed to a neoplastic disorder comprising at least one container having a CD23 antagonist deposited therein and a label or an insert indicating that said CD23 antagonist may be used to treat said neoplastic disorder.
52. The kit of claim 51 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
53. The kit of claim 51 wherein said CD23 antagonist is a monoclonal antibody.
54. The kit of claim 53 wherein said monoclonal antibody is IDEC-152.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of indicating an outcome of a football field goal attempt, comprising:
locating from a single video image that is a part of a live video broadcast of a football game, an initial position at which a football will be placed on a playing field during the execution of said field goal attempt, said initial position being located in a plane of a football field on which said event is occurring and being determined as a 2-D position relative to a location of a base of a goal post being aimed at;
obtaining, after a predetermined time period, said predetermined time period starting when a football player’s foot strikes said football, a single 3-D position of said kicked football relative to said initial position using a single, coordinated pair of images taken from two still-image cameras;
using said single 3-D position of said kicked football to mathematically determine a future trajectory of said kicked football;
using said mathematically determined future trajectory to predict whether or not said kicked football will pass through an imaginary success rectangle located in a plane of said goal post being aimed at, said imaginary success rectangle having the goal post cross-bar as a lower, short side, and wherein the two long sides of the imaginary success rectangle include the goal post uprights and their imaginary extension vertically upwards for an infinite distance; and
if said prediction is indicative, within a predefined threshold of uncertainty, of being a successful field goal kick, displaying on said live video broadcast, prior to the kicked football reaching the plane containing said goal post, a legible indicia indicative of said predicated success; or
if said prediction is indicative, within a predefined threshold of uncertainty, of being an unsuccessful field goal kick, displaying on said live video broadcast, prior to the kicked football appearing to reach the plane containing said goal post, a legible indicia indicative of said predicated lack of success; and
wherein said legible indicia is a virtual graphic element made to appear to be a part of said live video broadcast by use of pattern recognition technology.
2. The method of claim 1, wherein said predefined threshold of uncertainty comprises an 80% or more chance of being a correct prediction.
3. The method of claim 1, wherein said predefined threshold of uncertainty comprises a 90% or more chance of being a correct prediction.
4. The method of claim 1, wherein said predefined threshold of uncertainty comprises a 99% or more chance of being a correct prediction.
5. The method of claim 1 further comprising adding video elements to said live video broadcast that make said goal post uprights appear to extend upward in height to at least the predicted height of the football as it passes through the plane of said goal post being aimed at.
6. The method of claim 1 wherein said two still-image cameras are digital cameras that produce black and white images.